Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leish G1 cream versus intralesional meglumine antimonate for cutaneous leishmaniasis
IRCT20180115038383N1Phase 3Completed
- Sponsor
- Shahed University
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Shahed University. Primary endpoint: Wound healing. Started Feb 2018; status: completed.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20180115038383N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180115038383N1.